This trial is testing a new drug to treat bladder cancer. The new drug is being tested against the standard treatment to see if it is more effective.
- Non-muscle Invasive Bladder Cancer
2 Primary · 6 Secondary · Reporting Duration: 48 months
Awards & Highlights
2 Treatment Groups
1 of 2
1 of 2
596 Total Participants · 2 Treatment Groups
Primary Treatment: BCG+N-803 · No Placebo Group · Phase 1 & 2
Who is running the clinical trial?
Age 18+ · All Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is this a pioneering endeavor in the field of medical research?
"ImmunityBio, Inc. first trialled BCG+N-803 in 2014 and has since conducted a total of 30 investigations across 332 cities and 1 nation. At present, 20 trials are still ongoing from the initial 596 participants enrolled at Phase 1 & 2 stage." - Anonymous Online Contributor
Does this trial currently have vacancies?
"Affirmative. Clinicaltrials.gov records show that this research endeavour, which began on July 21st 2014, is still actively searching for participants. A total of 596 volunteers are needed across 10 different clinical sites." - Anonymous Online Contributor
What is the current size of cohort enrolled in this investigation?
"This medical study necessitates the enrolment of 596 patients that are eligible under it criteria. Potential participants may register in locations such as UCLA Department of Urology in Los Angeles, New Hampshire and Dartmouth-Hitchcock Medical Center in Lebanon, North Carolina." - Anonymous Online Contributor
What is the geographic scope of this experiment's supervision?
"10 clinical centres are offering this trial, including UCLA Department of Urology in Los Angeles, Dartmouth-Hitchcock Medical Center in Lebanon and Associated Urologists of North Carolina in Raleigh. Additional locations exist too." - Anonymous Online Contributor
Are there any supplementary investigations that have employed BCG+N-803?
"Arkansas Urology initiated the investigation of BCG+N-803 in 2014. Since then, 30 studies have been concluded and there are 20 ongoing trials occurring primarily in Los Angeles and New Hampshire." - Anonymous Online Contributor
What is the aim of this investigation?
"The primary endpoint of this projected 12-month study will be to evaluate Disease Free Survival (DFS). Secondary outcomes include Time to Disease Worsening, Time to Cystectomy, and Overall Survival." - Anonymous Online Contributor